BioMarin, a leading pharmaceutical company, has announced its acquisition of Inozyme Pharma based in Boston for a substantial $270 million. This strategic move is poised to enhance BioMarin’s portfolio and capabilities in the biotech industry. Inozyme Pharma is known for its innovative approach to developing therapies for rare mineralization disorders, making it a valuable addition to BioMarin’s pipeline. The acquisition signifies BioMarin’s commitment to advancing novel treatments and expanding its reach in the pharma sector.
Read more from bizjournals.com
